You are here

Share:

Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases

Summary
Researchers at the NCI have developed a method of improving the immune response in cancer immunotherapy by exploiting in the role of the Linker Adapted for T-Cell Signaling (LAT) molecule. The LAT molecular can enhance signaling through TCRs, thus, improving a patient’s own immune response to cancer or infectious diseases.
NIH Reference Number
E-159-2009
Product Type
Keywords
  • immunotherapy, LAT, T-Cells, TCR
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

One problem with the development of immunotherapy for cancer or other diseases is the inability to stimulate a sufficient immune response in patients to tumor associated antigens. The Linker Adapted for T Cell Signaling molecule (LAT) has been shown to be an important molecule in T cell signaling. The inventions described and claimed in this patent application illustrate a new supportive role for LAT which may be harnessed to improve a patient's immune response to tumor-associated antigens.

A number of approaches to improving the immune response in cancer immunotherapy have been investigated. One such approach is to be able to influence the potency of T Cell Signaling. This invention exploits the role of LAT in T Cell signaling and provides a means to create a more intense and effective T Cell response. This would have the end result of improving the overall response of a patient's immune system to the presence of tumor-associated antigens.

With T Cell signaling being important in the body's immune response to bacterial and viral antigens it may also be possible to harness the modified LAT molecules to improve the immune response in developing immunotherapy for infectious disease.

Potential Commercial Applications

Improve the overall response of a patient's immune system to tumor associated antigens.
Improve the overall response of a patient's immune system to bacterial associated antigens.
Improve the overall response of a patient's immune system to viral associated antigens.

Competitive Advantages
  • Enhanced T Cell Signaling should improve the overall effectiveness of immunotherapy producing a more robust patient response.
Inventor(s)

Lawrence Samelson (NCI), Lakshmi Balagopalan (NCI)

Development Stage
Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 61/176,231, Filed 07 May 2009
  • Foreign Filed: Foreign Filed - Patent Application PCT/US2010/033186, Filed 30 Apr 2010
  • U.S. Patent Issued: U.S. Patent Number 8799095, Issued 15 Jul 2014
  • U.S. Patent Issued: U.S. Patent Number 9649339, Issued 16 May 2017
Related Technologies
  • E-010-1998
Therapeutic Area
Posted
Tuesday, October 10, 2017